Pfizer gets first approval, in UK, for Xeljanz follow-up CibinqoPfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the Share XPfizer gets first approval, in UK, for Xeljanz follow-up Cibinqohttps://pharmaphorum.com/news/pfizer-gets-first-approval-in-uk-for-xeljanz-follow-up-cibinqo/
AbbVie’s Rinvoq cleared in EU for atopic dermatitisThe FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has Share XAbbVie’s Rinvoq cleared in EU for atopic dermatitishttps://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/
Look out Dupixent, Lilly’s lebrikizumab is on the marchEli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic Share XLook out Dupixent, Lilly’s lebrikizumab is on the marchhttps://pharmaphorum.com/news/look-out-dupixent-lillys-lebrikizumab-is-on-the-march/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drugPfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in Share XFDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drughttps://pharmaphorum.com/news/fda-sets-april-verdict-for-pfizers-underestimated-atopic-dermatitis-drug/
LEO eyeing 2021 US launch for eczema drug tralokinumabLEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the Share XLEO eyeing 2021 US launch for eczema drug tralokinumabhttps://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/
Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUThe EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic Share XEyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUhttps://pharmaphorum.com/news/eyeing-dupixents-territory-leo-pharma-files-tralokinumab-in-eu/
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmaNICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in Share XNICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/nice-rejects-nhs-funding-sanofi-regenerons-dupixent-in-asthma/
